We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Galapagos Enters Three-year Collaboration with Roche
News

Galapagos Enters Three-year Collaboration with Roche

Galapagos Enters Three-year Collaboration with Roche
News

Galapagos Enters Three-year Collaboration with Roche

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Galapagos Enters Three-year Collaboration with Roche "

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Galapagos NV has announced that Galapagos' service division, BioFocus, has entered into three-year collaboration with Roche. This agreement builds on the working history between Roche and BioFocus.
 
Under the terms of the agreement, BioFocus will supply Roche with exclusive chemical compound libraries. 

BioFocus will synthesize chemical compound libraries based on Roche's framework structures and provide these collections on an exclusive basis to Roche. 

These libraries will be generated using a combination of BioFocus' molecular informatics tools and a wide range of synthetic chemistry capabilities. 
 
BioFocus designs and synthesizes both exclusive as well as non-exclusive (SoftFocus®) chemical compound libraries that can be used in drug discovery programs, including hit finding, lead optimization and patent exemplification.
 
"We are very pleased with this new agreement to deliver exclusive compound libraries to complement Roche's drug discovery programs," said Onno van de Stolpe, CEO of Galapagos. 

"With a strong set of design tools and world-class synthetic chemistry capabilities, BioFocus continues to secure new business by providing high-quality libraries to the pharmaceutical and biotech industries."

Advertisement